Stock Events

Stock Events

Arch Biopartners 

€0.5750
12
+€0.00+0.35% 07:55 Today

Statistics

Day High
0.575
Day Low
0.574
52W High
0.745
52W Low
0.25
Volume
-
Avg. Volume
-
Mkt Cap
38.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31AugExpected
Q4 2025
Q1 2026
Next
-0.01
0.32
0.65
0.99
Expected EPS
N/A
Actual EPS
N/A

Financials

-554.3%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
175,903.3Revenue
-975,036.17Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8HA.F. It's not an investment recommendation.
Enbridge
4
ENB.TO
Tourmaline Oil
4
TOU.TO
Hamilton Enhanced U.S. Covered Call (CAD Hedged units)
3
HYLD.TO
Hamilton Enhanced Canadian Covered Call
3
HDIV.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, similar to Arch Biopartners' focus on critical diseases including bacterial infections and inflammation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, particularly in developing monoclonal antibodies, a field where Arch Biopartners is also active.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a competitor due to its strong presence in the antiviral and anti-inflammatory drug market, areas that overlap with Arch Biopartners' research interests.
AMGEN
AMGN
Mkt Cap236.38B
Amgen competes with Arch Biopartners in the biotech space, focusing on innovative therapeutics, including treatments for inflammatory diseases.
Biogen
BIIB
Mkt Cap32.63B
Biogen is a competitor because of its focus on developing therapies for neurological and neurodegenerative diseases, competing with Arch Biopartners' interest in novel drug candidates.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie is a competitor as it has a broad portfolio of biopharmaceuticals, including anti-inflammatory and antiviral drugs, overlapping with Arch Biopartners' areas of interest.
Pfizer
PFE
Mkt Cap162.16B
Pfizer competes with Arch Biopartners through its extensive research and development in various therapeutic areas, including anti-infectives.
Merck
MRK
Mkt Cap370.89B
Merck is a competitor because of its global healthcare presence and focus on pharmaceuticals that address serious health issues, similar to Arch Biopartners' mission.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a competitor due to its wide range of therapeutic products, including treatments for infections and chronic diseases, areas where Arch Biopartners is also active.
Novartis
NVS
Mkt Cap304.1B
Novartis competes with Arch Biopartners in the global healthcare market, focusing on innovative medicines, including those for infectious and inflammatory diseases.

About

Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys. This inflammation is a key factor in organ damage or failure, often seen in severe conditions such as sepsis and COVID-19. Additionally, the company is progressing with AB569, an investigational drug aimed at combating or deterring antibiotic-resistant bacterial infections, predominantly through topical application for wounds. Further expanding their portfolio, Arch Biopartners is developing Borg, a peptide-based technology that interfaces with solid surfaces to inhibit biofilm formation and reduce corrosion. Another distinct project is MetaMx, which consists of synthetic molecules specifically engineered to target brain tumor initiating cells and aggressive glioma cells. The company is headquartered in Toronto, Canada.
Show more...
CEO
Richard Gabriel Muruve
Employees
6
Country
Canada
ISIN
CA03938C1041
WKN
000A1CYFF

Listings

F
DE
8HA.F
V
CA
ACH.V
V
CA
ARCH.V
OTC Link
US
ACHFF

0 Comments

Share your thoughts

FAQ

What is Arch Biopartners stock price today?▼
The current price of 8HA.F is €0.58 EUR — it has increased by +0.35% in the past 24 hours. Watch Arch Biopartners stock price performance more closely on the chart.
What is Arch Biopartners stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Arch Biopartners stocks are traded under the ticker 8HA.F.
What is Arch Biopartners market cap?▼
Today Arch Biopartners has the market capitalization of 38.94M
When is the next Arch Biopartners earnings date?▼
Arch Biopartners is going to release the next earnings report on February 02, 2027.
What is Arch Biopartners revenue for the last year?▼
Arch Biopartners revenue for the last year amounts to 175,903.3 EUR.
What is Arch Biopartners net income for the last year?▼
8HA.F net income for the last year is -975,036.17 EUR.
How many employees does Arch Biopartners have?▼
As of September 08, 2026, the company has 6 employees.
In which sector is Arch Biopartners located?▼
Arch Biopartners operates in the Health & Wellness sector.
When did Arch Biopartners complete a stock split?▼
Arch Biopartners has not had any recent stock splits.
Where is Arch Biopartners headquartered?▼
Arch Biopartners is headquartered in Toronto, Canada.